For the Inventor, By the Inventor

Enter assignee name

Vienna, VA, United States of America

Cel-Sci Corporation

USPTO Granted Patents = 16

% Expired Patents = 12.5

EPO Patents = 6

Trademarks = 1

Forward Citations = 69

Loading Chart...

Loading Chart...

7 inventors (with patents filed for the assignee):

Daniel H Zimmerman (14 out of 18 patents)

Eyal Talor (4 out of 4 patents)

Prem S Sarin (4 out of 6 patents)

4. Kenneth Rosenthal (2 out of 2 patents)

5. Donald A Elliott (2 out of 3 patents)

6. Kanta Subbarao (1 out of 6 patents)

7. Kobporn Boonnak (1 out of 1 patent)

8. Katalin Mikecz (1 patent)

9. Harold Steiner (0 patent)

10. Roy Carambula (0 patent)

11. Tibor Glant (0 patent)

12. Geert Kersten (0 patent)

16 patents: Sort by Forward Citations

1. 11041013 - Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis (2021-06-22),

2. 10238747 - Method for inducing an immune response against avian, swine, spanish, H1N1, H5N9 influenza viruses and formulations thereof (2019-03-26),

3. 10179174 - Method for inducing an immune response and formulations thereof (2019-01-15),

4. 10179164 - Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions (2019-01-15),

5. 7256254 - Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions (2007-08-14),

6. 7199216 - Peptide constructs for treating autoimmune and related diseases (2007-04-03),

7. 6995237 - Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions (2006-02-07),

8. 6951647 - T cell binding ligand peptides and method of inducing a cellular immune response (2005-10-04),

9. 6896879 - Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture (2005-05-24),

10. 6572860 - Immunogenic conjugated polypeptide for treatment of herpes simplex virus (2003-06-03),

11. 6287565 - Modified HGP-30 heteroconjugates, compositions and methods of use (2001-09-11),

12. 6268472 - Modified HGP-30 peptides, conjugates, compositions and methods of use (2001-07-31),

13. 6103239 - Modified HGP-30 heteroconjugates, compositions and methods of use (2000-08-15),

14. 6096315 - Heterofunctional cellular immunological reagents, vaccines containing (2000-08-01),

15. 6093400 - Modified HGP-30 peptides, conjugates, compositions and methods of use (2000-07-25),

Company Overview

Cel-Sci Corporation is a biotechnology company based in Vienna, Virginia, focused on the development of innovative immunotherapy treatments for cancer and infectious diseases. The company specializes in leveraging its proprietary technology to enhance the immune response against tumors, aiming to improve patient outcomes. Cel-Sci's research encompasses a range of therapeutic approaches, including its lead product candidate, which is designed to stimulate the immune system to target and destroy cancer cells.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

16 Patents

#9 in Vienna, VA

#332 in Virginia

#19,922 in US

#37,831 in the World

Vienna, VA, United States of America

Cel-Sci Corporation

Forward Citations = 69

7 inventors:

Daniel H Zimmerman (14 out of 18 patents)

Eyal Talor (4 out of 4 patents)

Prem S Sarin (4 out of 6 patents)

4. Kenneth Rosenthal (2 out of 2 patents)

5. Donald A Elliott (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cel-Sci Corporation. Retrieved from https://idiyas.com/company/cel-sci

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…